文献速递骨软组织肉瘤与黑色素瘤

靶向CD20的CAR-T细胞治疗晚期黑色素瘤的I期试验结果

Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial.
PubMed 文献 · Eur J Cancer · 2026-10-17

这项前瞻性开放标签I期试验采用3+3设计,评估自体抗CD20 CAR-T细胞(MB-CART20.1)治疗难治性晚期黑色素瘤的安全性和初步活性。3例接受DL1(1.0×10⁵ cells/kg),4例接受DL2(1.0×10⁶ cells/kg);DL2出现2例剂量限制性毒性(3级ICANS和4级肝毒性),无持久临床获益,试验提前终止。

要点

  • DL1未出现剂量限制性毒性,DL2出现2例剂量限制性毒性。
  • 3例患者在16周时达疾病稳定,但均在6个月前进展。
  • MB-CART20.1体内扩增显著,但DL2严重毒性且无持久获益致试验终止。

核心结论

  • MB-CART20.1在晚期黑色素瘤中伴随显著扩增和毒性,Breg耗竭和黑色素瘤典型治疗史可能驱动了独特的CAR-T相关免疫毒性。

研究设计与样本

  • 前瞻性、开放标签、3+3设计的I期试验,纳入晚期黑色素瘤且对已批准治疗难治的患者。
  • 淋巴细胞清除化疗后单次输注自体抗CD20 CAR-T细胞MB-CART20.1,3例接受DL1(1.0×10⁵ cells/kg),4例接受DL2(1.0×10⁶ cells/kg)。
  • 主要终点为安全性和耐受性,次要终点包括动力学和抗肿瘤活性早期证据。

主要发现

  • DL1无剂量限制性毒性,DL2有2例剂量限制性毒性(3级ICANS和4级肝毒性)。
  • 全部7例患者共报告43例严重治疗中出现的不良事件。
  • 3例患者在16周时达疾病稳定,但均在6个月前进展。
  • 所有患者在白细胞分离前6个月内接受过免疫检查点抑制剂,CD8+ T细胞耗竭标志物表达降低。
  • CD19+CD24+CD27+ Breg细胞频率趋势与疾病进展相关,并与毒性呈负相关。

临床怎么用

  • DL2(1.0×10⁶ cells/kg)出现严重剂量限制性毒性且无持久获益,不支持该剂量进一步开发。
  • 治疗前6个月内接受免疫检查点抑制剂的患者需警惕CAR-T相关免疫毒性。

局限性

  • 样本量小(共7例),为早期I期试验。
  • 因DL2严重毒性且无持久临床获益,试验提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies identified CD20+ cells within the melanoma tumor microenvironment, including tumor-associated B-cells and putative cancer stem cells (CSC), as potential therapeutic targets. We therefore evaluated CD20-targeting CAR T-cells in patients with advanced melanoma. METHODS: This prospective, open-label phase I trial evaluated a 3 +3 design in patients with advanced melanoma, refractory to approved treatments, to assess safety and preliminary activity of autologous anti-CD20 CAR T-cells (MB-CART20.1). Following lymphodepleting chemotherapy, patients received a single MB-CART20.1 infusion. Primary endpoints were safety and tolerability; secondary endpoints included kinetics and early evidence for antitumor activity. Three patients received dose level 1 (DL1) (1.0 ×10⁵ cells/kg) and four patients DL2 (1.0 ×10⁶ cells/kg). RESULTS: No DLTs occurred at DL1, while two patients experienced DLTs at DL2 (grade 3 ICANS and grade 4 hepatotoxicity). Overall, 43 serious TEAEs were reported across all seven patients. Stable disease was observed in three patients at week 16; all had progressed by month 6. All had received immune checkpoint inhibitors within 6 months before leukapheresis and showed reduced exhaustion marker expression on CD8+ T-cells. In addition, the frequency of CD19+CD24+CD27+ Breg cells trended to associate with progressive disease and inversely correlate with toxicity. MB-CART20.1 showed robust in vivo expansion however, severe DLTs at DL2 without durable clinical benefit led to early trial termination. CONCLUSIONS: In advanced melanoma, MB-CART20.1 was associated with marked expansion and toxicity, suggesting that Breg depletion and the melanoma-typical treatment history might have driven distinct CAR T-associated immunotoxicities.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Balke-Want H, Theurich S, Gödel P, et al. Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial. Eur J Cancer. 2026. PMID: 42913258. doi:10.1016/j.ejca.2026.117780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。